By annette
The Swedish Institute for Health Economics and the Bengt Jönsson Foundation for Health Economics Research are pleased to announce a scholarship of 50,000 SEK awarded to the best bachelor’s or master’s thesis in health economics and related topics for the academic year 2023/2024. Read more
By annette
The IHE Type 2 Diabetes Cohort Model (IHE-DCM-T2) is frequently used to estimate cost-effectiveness of interventions for type 2 diabetes in different parts of the world. The model has recently been updated to include Japanese risk equations, and in a study presented at ISPOR we illustrate how the choice between the Japanese and Western risk …
By annette
On April 9, 2024 IHE participates in the roundtable event “Fighting Lung Cancer Together as Equals – a Year On” under the patronage of MEP Cristian-Silvio Bușoi in the European Parliament. Thomas Hofmarcher and Bardh Manxhuka presents key findings of the recently published IHE Report 2024:5. This report follows up on the original Call to …
By annette
Researchers from IHE have investigated the perceived disease burden among people with experience of moderate to severe acute allergic reactions. The study characterized people with experience of moderate to severe AARs and evaluated their self-reported disease burden Read more
By annette
How good are European health systems in publishing real-world data (RWD) on quality indicators in cancer care? This report looks at the example of drug treatment rates in advanced-stage non-small cell lung cancer (aNSCLC). Read more
By annette
The report explores current challenges and opportunities to improve the care of women with TNBC. The report is available in English and Spanish. Read more
By annette
Austria’s National Cancer Plan turns 10 years in 2024. To mark this anniversary, Thomas Hofmarcher went to Vienna to present an assessment of Austria’s cancer care system at the event “10 Jahre Nationales Krebsrahmenprogramm in Österreich” in the Austrian Parliament. In a European comparison, cancer patients in Austria fare comparatively well, but there is still …
By annette
Health technology assessment (HTA) decisions for pharmaceuticals are complex and evolving. New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence and budget impact at the time of market entry. Real-world evidence (RWE), has been suggested as a means to support HTA decisions for rare disease …
By annette
The Swedish Institute for Health Economics welcomes Marcela Urey-Adamsson and Jad Shedrawy who joined our team in January and they both work as research manager, Marcela at the Lund office and Jad at the Stockholm office.
By annette
The OECD just published a new report about cancer care in Europe with input from IHE. The report puts a spotlight on the disease burden, cancer prevention, early detection, and the sustainability of cancer care systems. Read more and download the report